Abstract
Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.
Original language | English (US) |
---|---|
Pages (from-to) | 3558-3561 |
Number of pages | 4 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 49 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2005 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases